WILLIAM LAMAR KERR
Medical Practice in Tampa, FL
License number
Pennsylvania MD072552L
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
2
Tampa, FL 33634
Pennsylvania
Pennsylvania
Personal information
See more information about WILLIAM LAMAR KERR at radaris.comName
Address
Phone
500 Palm Springs Blvd APT 413, Indian Harbour Beach, FL 32937
5106 Oleander Dr, Tallahassee, FL 32305
4745 Fairfield Rd, Fairfield, PA 17320
444 Dietz Estates Dr, York, PA 17404
4525 Cove Cir APT 1003, Saint Petersburg, FL 33708
Professional information
Lps-Responsive -Like Anchor Gene And Therapeutic Applications Thereof
US Patent:
7704963, Apr 27, 2010
Filed:
Apr 2, 2002
Appl. No.:
10/473741
Inventors:
William G. Kerr - Tampa FL, US
Jia-Wang Wang - Tampa FL, US
Jia-Wang Wang - Tampa FL, US
Assignee:
University of South Florida - Tampa FL
International Classification:
A01N 43/04, C12Q 1/68, C12P 19/34, C07H 21/02, C07H 21/04
US Classification:
514 44, 435 6, 435 9131, 435455, 536 231, 536 2431, 536 245
Abstract:
The present invention relates to a novel LPS-responsive and Beige-like Anchor gene (lrba), variants of the lrba gene, fragments of the lrba gene, and polypeptides encoded thereby. The subject invention also pertains to lrba interfering RNA, and uses thereof. In another aspect, the present invention also includes methods of inhibiting tumor growth in a patient by suppressing lrba function.
Dr. William L Kerr, Tampa FL - MD (Doctor of Medicine)
Specialties:
Pediatrics
Address:
9119 Corporate Lake Dr SUITE 300, Tampa 33634
Certifications:
Pediatrics, 1996
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
University of Arkansas For Medical Sciences
Graduated: 1993
Baylor College Of Medicine
University of Arkansas For Medical Sciences
Graduated: 1993
Baylor College Of Medicine
Inhibition Of Ship To Enhance Stem Cell Harvest And Transplantation
US Patent:
7691821, Apr 6, 2010
Filed:
May 28, 2004
Appl. No.:
10/709801
Inventors:
Caroline Desponts - Tampa FL, US
Joseph Wahle - Tampa FL, US
John Ninos - Tampa FL, US
William G. Kerr - Tampa FL, US
Joseph Wahle - Tampa FL, US
John Ninos - Tampa FL, US
William G. Kerr - Tampa FL, US
Assignee:
University of South Florida - Tampa FL
International Classification:
A01N 43/04, C12N 5/08, C12P 19/34, C07H 21/02, C07H 21/04
US Classification:
514 44, 435 6, 435 911, 435372, 435455, 536 231, 536 245
Abstract:
The instant invention teaches the inhibition of SHIP expression, or function, for the increased efficacy of autologous stem cell transplants. In another embodiment, interference with SHIP function can be used to temporarily expand and mobilize the hematopoietic stem cell compartment to assist with leukapheresis, to promote hematopoietic recovery after myeloablation treatments, to deplete target stem cell clones (such a leukemic clones and other tumor stem cell types), and to deplete, or damage, the repopulating ability of the endogenous hematopoietic stem cell pool in order to allow transplanted hematopoietic stem cells to better home and engraft and to promote in vivo expansion and mobilization of other organ-specific stem cell populations (e. g. , mesenchymal, mammary).
Novel Sh2Containing Inositol 5'-Phosphatase Isoform That Partners With The Grb2 Adapter Protein
US Patent:
2007022, Sep 27, 2007
Filed:
Mar 19, 2007
Appl. No.:
11/726028
Inventors:
William Kerr - Tampa FL, US
John Ninos - Tampa FL, US
John Ninos - Tampa FL, US
Assignee:
University of South Florida - Tampa FL
International Classification:
C12N 15/87, A61K 49/00, C12N 5/00, G01N 33/53, C07H 21/04
US Classification:
424009100, 435375000, 435377000, 435461000, 435007210, 536023100
Abstract:
SH2 containing inositol 5′-phosphate (SHIP) modulates the activation of immune cells after recruitment to the membrane by Shc and the cytoplasmic tails of receptors. A novel SHIP isoform of approximately 104 kd expressed in primitive stem cell populations (s-SHIP) is described. It was found that s-SHIP is expressed in totipotent embryonic stem cells to the exclusion of the 145-kd SHIP isoform expressed in differentiated hematopoietic cells. s-SHIP is also expressed in primitive hematopoietic stem cells, but not in lineage-committed hematopoietic cells. In embryoic stem cells, s-SHIP partners with the adapter protein Grb2 without tyrosine phosphorylation and is present constitutively at the cell membrane. It is postulated that s-SHIP modulates the activation threshold of primitive stem cell populations.
Ship-Deficiency To Increase Megakaryocyte Progenitor Production
US Patent:
7807646, Oct 5, 2010
Filed:
Nov 22, 2004
Appl. No.:
10/904667
Inventors:
William G. Kerr - Tampa FL, US
Caroline Desponts - Tampa FL, US
Lia Elena Perez - Tampa FL, US
Caroline Desponts - Tampa FL, US
Lia Elena Perez - Tampa FL, US
Assignee:
University of South Florida - Tampa FL
International Classification:
A61K 48/00
US Classification:
514 44, 536 245, 536 2431, 536 241
Abstract:
A method of increasing megakaryocytes and platelet numbers in a patient comprising the step of inhibiting SHIP expression, including SHIP's enzymatic activity and signaling functions, whereby normal blood clotting is induced.
Control Of Nk Cell Function And Survival By Modulation Of Ship Activity
US Patent:
2002016, Nov 7, 2002
Filed:
Mar 14, 2002
Appl. No.:
10/097101
Inventors:
William Kerr - Tampa FL, US
Tomar Ghansah - Sarasota FL, US
Tomar Ghansah - Sarasota FL, US
International Classification:
A61K048/00, A01K067/027
US Classification:
514/044000, 800/018000
Abstract:
Inhibition of dendritic cell function in solid organ grafts or allogeneic bone marrow transplants prior to or during engraftment by blocking SH2-containing inositol phosphatase (SHIP) expression or function is taught as a method of abrogating immune rejection and thereby increasing the efficacy of engraftment of an allogeneic bone marrow transplant or solid organ allograft or xenograft. Also disclosed is a transgenic mouse having the genotype SHIP which exhibits enhanced survival following mismatched allogeneic marrow grafts.
Control Of Nk Cell Function And Survival By Modulation Of Ship Activity
US Patent:
7713945, May 11, 2010
Filed:
Apr 13, 2007
Appl. No.:
11/787064
Inventors:
William G. Kerr - Tampa FL, US
Assignee:
University of South Florida - Tampa FL
International Classification:
A61K 31/70
US Classification:
514 44
Abstract:
Inhibition of dendritic cell function in solid organ grafts or allogeneic bone marrow transplants prior to or during engraftment by blocking SH2-containing inositol phosphatase (SHIP) expression or function is taught as a method of abrogating immune rejection and thereby increasing the efficacy of engraftment of an allogeneic bone marrow transplant or solid organ allograft or xenograft. Also disclosed is a transgenic mouse having the genotype SHIP which exhibits enhanced survival following mismatched allogeneic marrow grafts.
Ship-Deficiency To Increase Megakaryocyte Progenitor Production
US Patent:
7763592, Jul 27, 2010
Filed:
Jun 12, 2006
Appl. No.:
11/451004
Inventors:
William G. Kerr - Tampa FL, US
Caroline Desponts - Temple Terrace FL, US
Lia Elena Perez - Tampa FL, US
Caroline Desponts - Temple Terrace FL, US
Lia Elena Perez - Tampa FL, US
Assignee:
University of South Florida - Tampa FL
International Classification:
A61K 48/00
US Classification:
514 44, 536 245, 536 2431, 536 241
Abstract:
The invention concerns a method for increasing megakaryocyte and megakaryocyte progenitor numbers in vitro or in vivo by suppressing SH2-containing inositol-5-phosphatase (SHIP) function in megakaryocytes or megakaryocyte progenitors expressing the SHIP gene. SHIP function can be suppressed by administering an interfering RNA, or other SHIP inhibitor, to the megakaryocytes or megakaryocyte progenitors in vitro or in vivo.
Control Of Nk Cell Function And Survival By Modulation Of Ship Activity
US Patent:
2002013, Sep 26, 2002
Filed:
Sep 19, 2001
Appl. No.:
09/955174
Inventors:
William Kerr - Tampa FL, US
International Classification:
A61K048/00
US Classification:
514/044000, 424/093200
Abstract:
Suppression of hematopoietic-specific SH2-containing inositol polyphosphatase (SHIP) activity by genetic and pharmaceutical means is taught for suppression of rejection of, and prevention of graft-versus-host disease in, solid organ allografts or xenotransplants, and histo-incompatible marrow grafts. Also disclosed are methods for the screening of substances and genetic constructs that inhibit SHIP function in mammalian cells, and cell lines and transgenic animals that have the SHIP phenotype.